Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
Abstract Background Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and risk of...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | Journal of Nanobiotechnology |
| Online Access: | https://doi.org/10.1186/s12951-023-02206-5 |